Pharma News
08 Feb 2026 to 14 Feb 2026
Feb 14, 2026
FDA supports geo-tagging of pharmacies, while chemists claim it's a form of coercion - Drugscontrol
The Karnataka FDA's geo-tagging initiative for pharmacies has led to tensions, with the Bangalore District Chemists and Druggists Association claiming that officials and retailers are facing undue pressure. The FDA defends the move, emphasizing its importance for regulatory compliance and consumer safety.
Feb 14, 2026
Two Biotech Companies to Invest In as AI-Driven Drug Discovery Gains Momentum
Eli Lilly has agreed to acquire Orna Therapeutics for $2.4 billion, aiming to enhance its drug pipeline with innovative therapies using circular RNA technology. Orna's candidate, ORN-252, targets autoimmune diseases and is clinical trial-ready. Despite Lilly's success with tirzepatide, its stock has seen a 4% decline in 2026, prompting investors to consider other opportunities.
Feb 14, 2026
Novo Nordisk Undergoes Concurrent FDA Review and Legal Challenges Regarding Weight Loss Medications | The Swamp
Novo Nordisk faces increased scrutiny from the FDA and legal challenges related to its obesity drugs, Wegovy and Ozempic, which are based on semaglutide. As demand surges, the company must navigate safety monitoring, manufacturing quality, and potential lawsuits over side effects. The obesity drug market is projected to grow significantly, raising questions about treatment approaches and patient safety.
Feb 14, 2026
Which Pharmaceutical Stock Is Considered a Top Investment for the Next Decade?
Eli Lilly (NYSE: LLY) is actively expanding its drug pipeline, recently announcing a $2.4 billion acquisition of Orna Therapeutics and a $350 million collaboration with a Chinese biotech firm for immune disorder and cancer treatments. This follows a billion-dollar deal for hearing loss gene therapies, positioning Lilly as a leader in the GLP-1 drug category.
Feb 14, 2026
NDLEA states that patent medicine vendors are not permitted to sell or prescribe antibiotics and diabetes medications.
The NDLEA's Oyo State Command has warned patent medicine dealers against selling or prescribing antibiotics and other controlled drugs, including diabetic medications and strong painkillers. Commander Lawal Adetula emphasized the importance of compliance to avoid legal repercussions. The NDLEA will monitor dealers to ensure adherence, while NAPPMED members pledged to follow regulations.
Feb 14, 2026
Natco Pharma Receives Approval for Generic Semaglutide Amid Ongoing Patent Dispute - Whalesbook
Natco Pharma has received approval from India's CDSCO to manufacture a generic semaglutide injection, targeting a March 2026 launch. This comes amid ongoing patent disputes with Novo Nordisk, which could impact market entry. Other companies like Dr. Reddy's and Sun Pharma are also involved in similar legal challenges, highlighting the competitive landscape in the diabetes treatment market.
Feb 14, 2026
The surge of weight-loss products: India approaching a trend of unrestricted dieting solutions
India faces a growing obesity crisis, with 25.4 crore people affected. The launch of weight-loss drugs Mounjaro (tirzepatide) by Eli Lilly and Wegovy (semaglutide) by Novo Nordisk has led to increased demand, often fueled by self-prescription. Concerns about regulatory oversight and patient safety are rising as these drugs are easily accessible without proper medical consultation.
Feb 13, 2026
Costs, supply routes, and patent expirations: An overview of the significant changes in the pharmaceutical industry - CNBC
Europe's major pharma companies reported mixed earnings, but focus shifted to future strategies amid a looming "patent cliff." Notably, Sanofi's CEO Paul Hudson departed as the company prepares for patent expiries on Dupixent. Meanwhile, Novo Nordisk and Eli Lilly dominate the GLP-1 obesity drug market, facing competition from AstraZeneca, Roche, Pfizer, and Amgen.
Feb 13, 2026
ANALYSIS | Sanofi's incoming CEO must address the drug pipeline issues and manage relations with Trump.
Sanofi's incoming CEO, Belén Garijo, faces significant challenges in revitalizing the company's R&D pipeline and restoring investor confidence amid vaccine skepticism in the U.S. Garijo, previously at Merck, must address the reliance on Dupixent, which constitutes over 30% of revenue, and improve Sanofi's drug development track record. She is the first female CEO of a major global drugmaker.
Feb 13, 2026
Sanofi Appoints Belen Garijo as New CEO, Succeeding Paul Hudson Due to Challenges in Vaccine Sector
Sanofi has ousted CEO Paul Hudson amid pressure from U.S. vaccine challenges and a stalled turnaround since 2019. Belen Garijo, from Merck KGaA, will succeed him in late April. Hudson's tenure saw a 33% return for shareholders, significantly lower than rivals AstraZeneca and GSK. Analysts expect Garijo to enhance R&D productivity and prepare for Sanofi's future beyond its asthma drug Dupixent.
Feb 13, 2026
Has Eli Lilly Secured a Deal for Its Upcoming Major Drug? - Yahoo Finance
Eli Lilly has solidified its position in the GLP-1 drug market with tirzepatide, which became the best-selling drug globally. Recently, Lilly acquired Orna Therapeutics for $2.4 billion, aiming to develop innovative gene therapies, including ORN-252 for autoimmune diseases. Despite a 4% stock decline in 2026, Lilly continues to expand its pipeline with strategic collaborations.
Feb 13, 2026
Numerous advertisements for online pharmacies, including those promoting weight-loss medications, seem to breach federal regulations.
Several online pharmacies in Canada, including Rocky Health Inc. and Pocketpills, are facing scrutiny for violating drug advertising laws by promoting medications like Viagra and GLP-1s without adhering to regulations. Health Canada has noted non-compliance and is working with companies to address these issues, emphasizing the importance of patient safety in pharmaceutical advertising.
Feb 13, 2026
Has Eli Lilly Secured a Deal for Its Upcoming Major Drug? - Nasdaq
Eli Lilly has agreed to acquire Orna Therapeutics for $2.4 billion, aiming to enhance its drug pipeline with innovative therapies using circular RNA technology. Orna's candidate, ORN-252, targets autoimmune diseases and is in early-stage development. This acquisition follows Lilly's recent collaborations to develop treatments for immune disorders and cancer, as the company seeks to maintain its market position.
Feb 13, 2026
Expensive blockbuster GLP-1 medications are impacting users and many others as well.
The rising popularity of GLP-1 drugs, such as Wegovy, is significantly impacting health insurance costs, with about 30% of premium increases attributed to these medications, according to Harvard's Luca Maini. While the Trump administration aims to lower costs for Medicare users, access remains limited, leading to higher out-of-pocket expenses for many patients. Generic versions may emerge in the next five years, potentially reducing costs.
Feb 13, 2026
MRK Rises Over 7% Due to Enhanced Long-Term Outlook: Is It Still a Sell? - TradingView
Merck's stock (MRK) rose 7.4% following strong Q4 results, with earnings of $2.04 per share and sales of $16.40 billion. Despite a cautious 2026 outlook, Merck anticipates over $70 billion in potential pipeline revenue by the mid-2030s, driven by Keytruda, which accounts for 55% of sales. However, challenges include declining Gardasil sales and impending patent expirations.
Feb 13, 2026
Prior to the issues surrounding Hims' GLP-1 pill, its pharmacy partner was already facing increased scrutiny from state authorities.
Arizona regulators are investigating Strive Pharmacy for alleged ketamine misuse and improper distribution of prescription drugs, including compounding GLP-1 weight-loss drugs like semaglutide and tirzepatide. Complaints suggest Strive provided medications to a clinic selling them over the counter. The Arizona Board of Pharmacy is reviewing these issues amid ongoing scrutiny of Strive's compounding practices linked to Hims & Hers and major drugmakers like Eli Lilly and Novo Nordisk.
Feb 13, 2026
Analysis: Sanofi's incoming CEO must address the drug pipeline issues and manage relations with Trump - WTAQ
Sanofi has appointed Belén Garijo as its new CEO, making her the first woman to lead a major global drugmaker. Garijo, previously at Merck KGaA, faces challenges in revitalizing Sanofi's stalled drug pipeline and addressing vaccine skepticism in the U.S. Her priority will be to enhance R&D productivity, particularly in replacing the asthma drug Dupixent, which accounts for over 30% of revenues.
Feb 13, 2026
Sanofi names its first female CEO and dismisses Paul Hudson - Pharmacy Business
Sanofi has appointed Belén Garijo as its first female CEO, replacing Paul Hudson, who was ousted just before his contract renewal. Hudson's tenure faced challenges, including a stalled drug pipeline and pressure from US anti-vaccine policies. Garijo, previously at Merck KGaA, will assume her role in late April, as Sanofi seeks to revitalize its growth strategy.
Feb 13, 2026
Has Eli Lilly Secured a Deal for Its Upcoming Major Drug? - The Globe and Mail
Eli Lilly has agreed to acquire Orna Therapeutics for $2.4 billion, aiming to enhance its drug pipeline with innovative therapies using circular RNA technology. Orna's candidate, ORN-252, targets autoimmune diseases and is clinical trial-ready. This acquisition follows Lilly's recent collaborations to develop treatments for immune disorders and hearing-loss gene therapies, despite a slight decline in its stock this year.
Feb 13, 2026
Sanofi removes CEO Hudson following lack of progress in revitalizing the vaccine company | The Mighty 790 KFGO
Sanofi has ousted CEO Paul Hudson, appointing Belén Garijo from Merck KGaA as his successor, making her the first female CEO of the company. Hudson's tenure faced challenges, including a stalled drug pipeline and pressure on vaccine sales. Sanofi shares fell 3.5% following the announcement, reflecting concerns over Garijo's mixed record and the company's R&D transformation.
Feb 13, 2026
Zydus agrees to pay $120 million to Astellas to resolve patent dispute - The Hans India
Zydus Lifesciences will pay $120 million to Astellas Pharma to settle patent litigation over the medication Myrbetriq. The agreement allows Zydus to continue marketing its generic Mirabegron in the US and includes a prepaid licensing fee on units sold until September 2027. Zydus shares rose 2.20% to Rs 917.80 on BSE following the announcement.
Feb 13, 2026
Supreme Court permits patent mapping in the cancer medication conflict involving Squibb and Zydus.
The Delhi High Court's Division Bench modified an interim injunction against Zydus, allowing the launch of its anti-cancer drug ZRC 3276, a biosimilar. The court emphasized public interest in accessing life-saving drugs, especially as Squibb's patent expires in May 2026. The Supreme Court has permitted product-to-claim mapping to guide future decisions.
Feb 13, 2026
ICMR requires clinical trials to prioritize Indian demographics and lifestyle, according to DrugsControl Media Services.
The Indian Council of Medical Research (ICMR) has mandated that clinical trials in India must focus on the country's unique demographics and lifestyles, as most current medicines are based on trials conducted in Western countries. This initiative aims to ensure that medical research is more relevant to the Indian population.
Feb 13, 2026
Department of Pharmaceuticals requests feedback from stakeholders regarding the revised list of 354 medical devices that are exempt from GTE.
The Department of Pharmaceuticals (DoP) has invited comments from stakeholders on an amended list of 354 medical devices exempted from Global Tender Enquiry (GTE) restrictions. This move aims to gather feedback to refine the exemption list further.
Feb 13, 2026
From the Edge to the Negotiation Table: Pharmaceutical Mergers and Acquisitions in 2026 and Future Trends - Bristows Inquisitive Minds
The biopharmaceutical industry faces a significant wave of patent expirations in 2026, risking $200-$300 billion in annual sales, particularly for top drugs like Keytruda, Eliquis, and Opdivo. In response, companies are shifting towards strategic transactions, with increased reliance on licensing and alliances, as seen in major acquisitions by Johnson & Johnson and Merck. 2026 is anticipated to be transaction-heavy as firms seek to diversify portfolios.
Feb 13, 2026
MetaVia Obtains Multiple Patents Valid Until 2041 for Weight Loss Medication - Benzinga
MetaVia Inc. (NASDAQ:MTVA) shares rose 9.64% to $1.84 after announcing a robust intellectual property portfolio for its lead asset, DA-1726, aimed at treating obesity. The company holds 39 patents for DA-1726, with protection extending to 2041. Recent clinical data showed a 9% weight loss at the 48 mg dose, alongside improvements in waist size and blood sugar levels.
Feb 13, 2026
MetaVia Obtains Multiple Patents Valid Until 2041 for Weight Loss Medication - Finviz
MetaVia Inc. (NASDAQ:MTVA) shares rose 9.64% to $1.84 after announcing a robust intellectual property portfolio for its lead asset, DA-1726, aimed at treating obesity. The company holds 39 patents for DA-1726, with protection extending to 2041. Recent clinical data showed a 9% weight loss at the 48 mg dose, alongside improvements in waist size and blood sugar levels.
Feb 13, 2026
Has Eli Lilly Secured a Deal for Its Upcoming Major Drug? | The Motley Fool
Eli Lilly has acquired Orna Therapeutics for $2.4 billion, aiming to develop innovative autoimmune treatments using circular RNA technology. This includes the promising therapy ORN-252, which allows the body to generate necessary changes to combat diseases like multiple sclerosis. Despite recent stock fluctuations, Lilly continues to expand its pipeline with strategic collaborations and acquisitions.
Feb 13, 2026
Sanofi, the French vaccine manufacturer, has dismissed CEO Paul Hudson and appointed the head of Merck as his successor.
Feb 13, 2026
Eli Lilly Prepares $1.5 Billion Stockpile of Experimental Weight-Loss Medication Ahead of FDA Verdict
Eli Lilly and Company has amassed a $1.5 billion inventory of its experimental oral weight-loss drug, orforglipron, ahead of a U.S. FDA decision expected in April. The drug has received a fast-track review, potentially expediting approval. CEO Dave Ricks highlighted Medicare's coverage expansion as a key factor for broader access to orforglipron, amid rising competition from Novo Nordisk's Wegovy.
Feb 12, 2026
Pharmaceutical Patent Searches Require Improvement to Keep Pace with Contemporary Innovations
In 2026, traditional freedom-to-operate (FTO) analysis is deemed inadequate for managing risks in the evolving pharmaceutical landscape, particularly with biologics and AI-assisted inventions. Companies must adopt dynamic, technology-enabled FTO strategies that consider complex patent portfolios and jurisdictional differences. Sanandan Malhotra from Novo Nordisk emphasizes the need for cross-functional collaboration to enhance FTO effectiveness and support innovation.
Feb 12, 2026
CDMOs Announce Expansion Plans for Injectable Medications - Insights from the DCAT Value Chain
The global injectables drugs market is set for significant growth, driven by demand for biologics and specialty therapeutics. CDMOs like Vetter, Thermo Fisher Scientific, and Simtra BioPharma Solutions are expanding production capacities with new facilities and lines. Notable investments include Vetter's €480 million facility in Germany and Thermo Fisher's acquisition of Sanofi's site in New Jersey.
Feb 12, 2026
Sanofi removes CEO Hudson following lack of progress in revitalizing the vaccine company - ET Pharma
Sanofi has ousted CEO Paul Hudson amid pressure from U.S. vaccine challenges and a stalled turnaround since 2019. Belen Garijo, currently at Merck KGaA, will succeed him in late April. Sanofi's vaccine sales are projected to decline, and investors have seen lower returns compared to rivals AstraZeneca and GSK. Hudson's departure is part of a strategy to enhance R&D productivity.
Feb 12, 2026
Sanofi dismisses CEO Paul Hudson following lack of progress in revitalizing the vaccine company - Business Day
Sanofi has fired CEO Paul Hudson, appointing Belén Garijo from Merck KGaA as his successor, effective late April. Hudson's tenure faced challenges, including a stalled turnaround and underwhelming trial updates, particularly as the company prepares for the loss of patents on its asthma drug Dupixent. Analysts expect Garijo to enhance Sanofi's R&D productivity and strategic execution.
Feb 12, 2026
Sanofi removes CEO Hudson following lack of progress in revitalizing the vaccine company - CNBC
Sanofi has ousted CEO Paul Hudson after six years, appointing Belén Garijo from Merck KGaA as his successor, effective late April. Hudson's tenure faced challenges, including stalled drug development and pressure from U.S. vaccine policies. Sanofi's shares fell nearly 6% following the announcement, reflecting concerns over Garijo's low profile. Hudson's departure continues a trend of CEO exits in European pharma.
Feb 12, 2026
AbbVie Files Lawsuit Against HHS and CMS Over Botox's Inclusion in Drug Price Negotiation Initiative - BioSpace
AbbVie has filed a lawsuit against the Department of Health and Human Services, challenging the inclusion of its product Botox in the drug price negotiation program under the Inflation Reduction Act. AbbVie argues that Botox, being a plasma-derived product, should be exempt from negotiations. The lawsuit also claims the negotiations violate the First Amendment and constitute a taking without just compensation.
Feb 12, 2026
One Reason I Will Hold Onto My AbbVie Shares Forever - The Globe and Mail
AbbVie (NYSE: ABBV), the world's third-largest healthcare company, has demonstrated resilience and adaptability, crucial traits for long-term success. With a robust pipeline of around 90 clinical programs, including blockbuster drugs Skyrizi and Rinvoq, AbbVie continues to thrive post-Humira patent expiration. The company is also recognized as a Dividend King, boasting a 3.1% yield.
Feb 12, 2026
The Trump administration is being encouraged to invoke a federal statute to permit the production of generic GLP-1 medications.
Public Citizen has petitioned the Trump administration to authorize generic versions of GLP-1 drugs, sold by Novo Nordisk and Eli Lilly, citing "unjustifiably high" prices that strain federal and state budgets. The group argues that recent concessions for Medicare and Medicaid access are inadequate, potentially leaving many without affordable options for obesity and diabetes treatment.
Feb 12, 2026
Possible challenges as weight loss medications become available in generic form - Palatinate
Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, utilize semaglutide to reduce appetite and food intake. Approved for type-2 diabetes, Wegovy was launched in the UK in September 2023, followed by Mounjaro in November. While effective for weight loss, concerns arise over long-term effects and side effects. As patents expire, the market for generic semaglutide may expand, raising questions about prescription regulations.
Feb 12, 2026
Novo Nordisk's Patent Victory Reduces Threat of Generic Competition, Yet Pricing Concerns Remain - Simply Wall St
Novo Nordisk achieved a legal victory as Hims & Hers abandoned plans to market a copycat oral semaglutide product, following a lawsuit to protect patents for its weight loss drug, Wegovy. This outcome, alongside increased regulatory scrutiny on compounded GLP-1 drugs, strengthens Novo's market position amid ongoing pricing pressures and competition from companies like Eli Lilly.
Feb 12, 2026
NDLEA States That Patent Medicine Vendors Are Not Permitted to Sell or Prescribe Antibiotics and Diabetes Medications
The NDLEA's Oyo State Command has warned patent medicine dealers against selling or prescribing antibiotics and other controlled drugs, including diabetic medications and strong painkillers. Commander Lawal Adetula emphasized the importance of compliance to avoid legal repercussions. The sensitization aimed to prevent harmful drug dispensing and protect public health, with NAPPMED members pledging adherence to regulations.
Feb 12, 2026
Aspire Biopharma Submits Provisional Patent Application for Rapid-Acting Sublingual Powder
Aspire Biopharma Holdings, Inc. has filed a provisional patent for a new sublingual delivery system for ondansetron, the active ingredient in Zofran®. This innovative formulation aims to provide rapid relief from nausea caused by cancer treatments, reducing the onset time from 30 minutes to just minutes. The global ondansetron market is projected to grow from $1.4 billion in 2023 to $2.4 billion by 2032.
Feb 12, 2026
Zydus Compensates Astellas $120 Million to Resolve US Patent Dispute Over Generic Medication - Whalesbook
Zydus Lifesciences has settled US patent litigation with Astellas Pharma over Myrbetriq® (Mirabegron), agreeing to pay $120 million and a prepaid per-unit licensing fee until September 2027. This settlement allows Zydus to market its generic version in the US, concluding all related legal disputes, though it may impact profitability due to the significant cash outflow.
Feb 12, 2026
Sanofi removes CEO Hudson following lack of progress in revitalizing the vaccine company | 104.1 WIKY
Sanofi has ousted CEO Paul Hudson, appointing Belén Garijo from Merck KGaA as his successor, making her the first female CEO of the company. Hudson's tenure faced challenges, including a stalled drug pipeline and pressure on vaccine sales. Sanofi shares fell 3.5% following the announcement, reflecting concerns over Garijo's mixed record in R&D.
Feb 12, 2026
Chandauli Authorities Halt Smuggler of Fake Medications: 3,970 Imitation 'New Ortho Power' Seized
Chandauli police in Uttar Pradesh have arrested a trafficker and seized 3,970 counterfeit 'New Ortho Power' tablet packs in a recent anti-smuggling operation. The fake homeopathic medicines were intercepted before they could be distributed to neighboring states, highlighting ongoing efforts to combat drug counterfeiting.
Feb 12, 2026
Zydus resolves patent conflict over Mirabegron with Astellas for $120 million in the US.
Zydus Lifesciences and its US subsidiary have reached a settlement with Astellas Pharma regarding patent litigation over Myrbetriq. Zydus will pay Astellas $120 million upfront and a licensing fee on generic Mirabegron sales until September 2027, resolving all disputes and permitting Zydus to market its generic version in the US.
Feb 12, 2026
Zydus Lifesciences settles US patent conflict over bladder medication for $120 million.
Zydus Lifesciences and its U.S. unit have agreed to pay $120 million to Astellas Pharma to settle a patent dispute over the bladder disorder drug Mirabegron. Additionally, they will pay a pre-paid per-unit licensing fee on sales of their generic Mirabegron in the U.S. until September 2027.
Feb 11, 2026
Novo's CEO criticizes the widespread use of GLP-1 medications as safety concerns intensify.
Novo Nordisk has filed a lawsuit against Hims & Hers Health, accusing the telehealth company of selling unapproved compounded versions of its semaglutide-based medications, including a copycat oral version of Wegovy. Novo's CEO, Mike Doustdar, criticized the mass compounding of GLP-1 drugs, emphasizing patient safety concerns. Hims & Hers defended its practices, claiming the lawsuit limits consumer choice.
Feb 11, 2026
Pallone: GOP Focusing on Drug Company Profits Instead of Patient Care
During a Health Subcommittee hearing, Ranking Member Frank Pallone criticized Republicans for failing to address healthcare affordability, particularly regarding prescription drug costs. He highlighted the negative impact of the "Big Ugly Bill," which he claims allows drugs like Keytruda to evade Medicare price negotiations, ultimately raising costs for patients. Pallone urged bipartisan support for the Lowering Drug Costs for American Families Act to enhance affordability.
Feb 11, 2026
Is Novo Nordisk's Recovery Narrative in Jeopardy Following Disappointing 2026 Projections? - TradingView
Novo Nordisk (NVO) reported better-than-expected Q4 and full-year results, driven by its semaglutide-based drugs, Ozempic and Wegovy. However, growth has slowed due to competition from Eli Lilly (LLY) and pricing pressures. The recent FDA approval of oral Wegovy offers potential, but NVO's weaker 2026 guidance has led to investor concerns and a stock sell-off.
Feb 11, 2026
Novartis' leader in biomedical research discusses artificial intelligence, streamlining the development pipeline, and a promising new drug.
Novartis is refining its drug pipeline by cutting six early-stage programs, primarily in solid tumors, as part of a strategy to focus on high-value medicines. This decision follows the company's 2023 reduction of 10% of its pipeline. Fiona Marshall, head of biomedical research, discussed these changes during the groundbreaking of a $1.1 billion research hub in San Diego.
Feb 11, 2026
Aishwarya Mohanraj's Journey of Weight Loss Using Mounjaro: Who is Suitable for GLP-1? - Times Now
A 31-year-old woman shared her experience with Eli Lilly's Mounjaro, a weekly injection containing tirzepatide, in a YouTube video. Since starting the treatment in August, she has discussed her struggles with weight gain, moving from 51 kg in early 2021 to 72-74 kg after marriage, highlighting the impact of societal expectations on body image.
Feb 11, 2026
Novartis Emphasizes AI Integration and Enhancing Its Pipeline as It Progresses with Potential...
Novartis is focusing on integrating artificial intelligence into its drug development processes while optimizing its pipeline. The company is prioritizing projects and discontinuing less promising ones. A potential blockbuster therapy is under development, showcasing Novartis' commitment to innovation in the competitive pharmaceutical industry.
Feb 11, 2026
Forecast and Size of the Generic Drug Market in the United States by 2025 | Trader - Vocal Media
The U.S. Generic Drugs Market is projected to grow from $95.87 billion in 2024 to $131.80 billion by 2033, driven by rising healthcare costs, an aging population, and patent expirations. Key players include Teva Pharmaceuticals, Aurobindo Pharma, and Sun Pharmaceuticals. Despite regulatory challenges and price volatility, generics are essential for affordable healthcare access in the U.S.
Feb 11, 2026
Viking Therapeutics: A GLP-1 Competitor That Growth Investors Should Pay Attention To
Viking Therapeutics is advancing its weight loss candidate VK2735 through promising phase 2 and phase 3 trials. The injectable and oral formulations of VK2735 could position Viking as a significant player in the GLP-1 market, currently dominated by Eli Lilly's Mounjaro and Novo Nordisk's Ozempic. Positive trial results may lead to substantial stock gains and potential regulatory approval.
Feb 11, 2026
DongKoo Bio & Pharma secures licensing for Novacell's atopic dermatitis treatment candidate NCP112 - KBR
DongKoo Bio & Pharma has licensed Novacell Technology’s peptide technology for its atopic dermatitis candidate NCP112. This collaboration aims to enhance DongKoo's dermatology pipeline and explore cosmeceuticals. Novacell's PEPTIROID platform targets inflammation and has secured approval for a phase 2 clinical trial in Korea, with plans to expand into other inflammatory diseases.
Feb 11, 2026
AstraZeneca experiences continued expansion, driven by its oncology medications - Yahoo Finance
AstraZeneca Plc anticipates profit growth this year, driven by cancer drug sales, as it navigates the patent expiry of its diabetes medication, Farxiga. CEO Pascal Soriot aims for $80 billion in revenue by 2030, with new treatments targeting obesity and lung cancer. Astra recently partnered with CSPC Pharmaceutical Group for innovative weight-loss solutions.
Feb 11, 2026
Novo Nordisk initiates patent litigation against Hims for its Wegovy imitations - WHTC
Novo Nordisk has filed a U.S. patent lawsuit against Hims & Hers over its compounded version of the weight-loss drug Wegovy, which contains the active ingredient semaglutide. This marks Novo's first patent infringement case against a compounder, following the FDA's declaration that semaglutide is no longer in short supply. The lawsuit signals a significant escalation in Novo's legal strategy against compounding pharmacies.
Feb 11, 2026
OneSource Pharma and Hikma receive regulatory clearance to market generic Ozempic in Saudi Arabia.
OneSource Specialty Pharma has received approval for its generic version of Ozempic, a type-2 diabetes and weight-loss drug, in Saudi Arabia, partnering with Hikma Pharmaceuticals PLC for commercialization in the MENA region. This move aims to meet rising demand for affordable alternatives as Novo Nordisk's patent for semaglutide expires in over 80 countries.
Feb 11, 2026
Shared Ownership Could Hinder the Introduction of More Affordable Generic Medications - ProMarket
Research by Martin Schmalz and Jin Xie reveals that U.S. pharmaceutical firms, particularly generic manufacturers, may harm their own value to benefit shareholders with stakes in rival brand-name companies. This behavior contradicts the Fisher separation theorem and suggests a need for antitrust laws to scrutinize passive investments in competitors. The study highlights the implications of common ownership in the industry.
Feb 11, 2026
Gilead Claims Cipla is Avoiding Previous Descovy Patent Agreement - Bloomberg Law News
Gilead Sciences Inc. has filed a federal lawsuit against Cipla Ltd. to block its proposed copy of the HIV drug Descovy, claiming it infringes seven patents related to tenofovir alafenamide, one of Descovy's active ingredients. The lawsuit was filed in the US District Court for the District of Delaware, alleging misuse of Gilead's clinical data for FDA approval.
Feb 11, 2026
With the swift growth of the global pharmaceutical and biotechnology sectors, there is an increasing range of conditions they are addressing...
A report by Samil PwC highlights the evolving landscape of the global pharmaceutical and bio industries, emphasizing the importance of speed and feasibility post-innovation. Key strategies include internalizing AI, enhancing clinical design capabilities, and ensuring supply chain stability. The report suggests that domestic companies must focus on quality and operational excellence to remain competitive in a rapidly changing market.
Feb 11, 2026
Hims & Hers Withdraws Imitation Wegovy Medication Following FDA Warnings - Everyday Health
Hims & Hers has withdrawn its compounded semaglutide pill, a copycat of Novo Nordisk's Wegovy, just two days after launch due to legal threats from the FDA and a lawsuit from Novo Nordisk for patent infringement. The FDA aims to restrict non-approved compounded drugs, raising concerns over safety and efficacy. The situation highlights tensions between drug accessibility and regulatory standards.
Feb 11, 2026
Supreme Court refuses to stop Zydus from marketing its cancer drug biosimilar, advises Bristol Myers to seek relief from High Court.
The Supreme Court of India upheld a Delhi High Court ruling allowing Zydus Lifesciences to market its biosimilar ZRC-3276, a version of Bristol Myers Squibb's anti-cancer drug Nivolumab, despite Squibb's patent expiring on May 2. The court emphasized the importance of public access to affordable cancer treatment, while allowing Squibb to investigate potential patent infringement.
Feb 11, 2026
Will Pfizer's Newly Developed and Acquired Medications Compensate for Its Upcoming Patent Expiration? - Yahoo Finance
Pfizer's COVID product sales, Comirnaty and Paxlovid, plummeted to $11 billion in 2024 and $6.7 billion in 2025 from $56.7 billion in 2022. Despite challenges, non-COVID revenues rose 6% in 2025, driven by products like Vyndaqel and Eliquis. Pfizer invested $9 billion in acquisitions, including Metsera, to bolster its pipeline and expects growth in obesity and oncology sectors.
Feb 11, 2026
Hims & Hers' Wegovy Imitation Pill Leads to Legal Action Following FDA Enforcement - Healthline
Hims & Hers has withdrawn its $49 compounded semaglutide weight loss pill after pressure from U.S. health officials and a lawsuit from Novo Nordisk, which claims patent infringement. The FDA and HHS raised concerns over the drug's legality, emphasizing consumer safety. Hims & Hers aims to provide safe, affordable care despite the setback.
Feb 11, 2026
Will Pfizer's Newly Developed and Acquired Medications Compensate for Its Upcoming Patent Expiration? - The Globe and Mail
Pfizer's COVID product sales, including Comirnaty and Paxlovid, plummeted to $11 billion in 2024 and $6.7 billion in 2025 from $56.7 billion in 2022. Despite challenges, non-COVID revenues rose 6% in 2025, driven by products like Vyndaqel and Eliquis. Pfizer's stock has increased 8.4% over the past year, but it holds a Zacks Rank #4 (Sell).
Feb 11, 2026
Popular weight loss medications such as Ozempic show significant effectiveness but raise important concerns.
Recent Cochrane reviews indicate that GLP-1 medications, including Ozempic, Mounjaro, and Victoza, can lead to significant weight loss. However, concerns arise over industry funding and potential conflicts of interest in the studies. The World Health Organization commissioned these reviews to shape future guidelines on obesity treatment, emphasizing the need for independent research and long-term safety data.
Feb 11, 2026
Novo Nordisk encounters a pivotal year in the obesity medication sector - CNBC
Novo Nordisk CEO Mike Doustdar outlined plans to combat competition from Eli Lilly's Zepbound and cheaper compounded versions of semaglutide, including Wegovy. With 246,000 patients on Wegovy, Doustdar aims to increase prescription volumes and address compounding issues. Despite challenges, he anticipates growth in 2026, especially with potential Medicare coverage for weight loss treatments.
Feb 10, 2026
Novo Nordisk challenges Hims & Hers following a $49 pill 'revival' | Americas
The Delhi High Court ruling adds to the challenges faced by the Danish pharma giant, which has recently seen its market value plummet by nearly $50 billion.
Feb 10, 2026
Novo Nordisk files lawsuit against Hims regarding abandoned $49 weight-loss medication imitation - BNN Bloomberg
Novo Nordisk has filed a patent infringement lawsuit against Hims and Hers Health after the telehealth company launched a $49 version of its weight-loss drug Wegovy, which was quickly canceled. The lawsuit highlights tensions between original drug manufacturers and compounding pharmacies. Novo seeks to ban Hims from selling the unapproved drug and recover damages, as competition in the obesity drug market intensifies.
Feb 10, 2026
Novo Nordisk Faces Legal Challenge Over Obesity Medication Patents and Potential Value Increase - Simply Wall St
Novo Nordisk has filed a lawsuit against Hims & Hers for patent infringement related to compounded oral semaglutide products, as competition in the obesity treatment market intensifies. The company is ramping up advertising for its drugs Wegovy and Ozempic amid a challenging market landscape, with its stock currently trading at $49.37, reflecting a mixed performance over recent years.
Feb 10, 2026
Eli Lilly Collaborates with Gene-Editing Company Seamless Therapeutics - National Today
Eli Lilly is partnering with Seamless Therapeutics to explore gene-editing treatments, particularly for hearing loss, as it prepares for the patent expiration of its GLP-1 drugs, Mounjaro and Zepbound, which significantly boosted sales in 2025. Additionally, Lilly is acquiring Ventyx Biosciences, focused on oral inflammation treatments, to diversify its product pipeline.
Feb 10, 2026
Top Selections: Eli Lilly Drives Positive Sentiment in Biotech with Growing Weight-Loss Drug Market
Geoff Meacham, global head of healthcare at Citi Bank, highlighted growth opportunities in biotech, particularly for Eli Lilly, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals. He noted the expanding applications of GLP-1 weight-loss drugs and the potential of Lilly's oral pill, Orforglipron. Meacham emphasized the importance of pipeline depth and upcoming clinical data for sustained growth in the sector.
Feb 10, 2026
Factors Expected to Propel AbbVie's Revenue Growth in 2026 - The Globe and Mail
AbbVie (ABBV) reported an 8.5% sales growth in 2025, driven by its immunology drugs Skyrizi and Rinvoq, which are expected to generate over $31 billion in combined sales. The company anticipates a 9.5% revenue increase in 2026, despite challenges in its oncology segment, particularly with Imbruvica. AbbVie is also expanding its neuroscience portfolio with new therapies.
Feb 10, 2026
Eli Lilly Teams Up with Gene-Editing Company Seamless Therapeutics: Details Inside...
Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, have driven a 225% stock price increase, but the company faces a potential patent cliff as these drugs account for 56% of sales. To mitigate future risks, Eli Lilly is investing in new opportunities, including a partnership with Seamless Therapeutics for gene editing and acquiring Ventyx Biosciences for inflammation treatments.
Feb 10, 2026
AstraZeneca Projects Increased Earnings in 2026 Driven by Cancer Treatment Success - FXLeaders
AstraZeneca Plc forecasts profit growth this year, driven by cancer drug sales, as it addresses the patent expiry of a major diabetes drug. The company expects earnings per share to rise by a low double-digit percentage. Additionally, AstraZeneca has partnered with CSPC Pharmaceutical Group for up to $18.5 billion to enhance its weight-loss medication pipeline.
Feb 10, 2026
Celltrion's Remsima solidifies its position as a leading global pharmaceutical product from South Korea - KED Global
Celltrion Inc.'s Remsima, the world's first biosimilar monoclonal antibody, is projected to surpass 1 trillion won ($713 million) in sales this year, making it Korea's first blockbuster drug. The drug, which received FDA approval in 2016, generated 979.7 billion won in sales in the first half of the year.
Feb 10, 2026
In Response to Talent Shortage, Radiopharma Sector Expands Recruitment Efforts - BioSpace
Investment in radiopharmaceuticals is intensifying competition for skilled talent, with companies like AstraZeneca, Bristol Myers Squibb, Eli Lilly, and Novartis seeking expertise in biopharma and nuclear science. Novartis' lutetium-177 therapies, Lutathera and Pluvicto, have spurred research, highlighting a talent gap in radiochemistry and nuclear engineering. Partnerships with universities aim to address workforce shortages as the sector anticipates significant growth.
Feb 10, 2026
Lilly invests $2.4 billion in Orna to advance next-generation cell therapy - WHTC
Eli Lilly is set to acquire Orna Therapeutics for up to $2.4 billion, gaining access to innovative technology that enables in-body therapy generation using patients' own cells. Orna's lead candidate, ORN-252, is a CAR-T therapy targeting CD19. This acquisition aims to enhance Lilly's oncology and immunology capabilities amid growing competition in the sector.
Feb 10, 2026
Korea continues to experience a significant gap in blockbuster drugs even after 25 years of approving domestic medications, according to KHIDI - KBR.
A new report from the Korea Health Industry Development Institute (KHIDI) highlights Korea's struggle to produce a global blockbuster drug, despite developing 38 new medicines over 25 years. It suggests focusing on niche diseases with high unmet needs and recommends partnerships to enhance capabilities. The report calls for increased support for late-stage development and regulatory improvements to bridge the blockbuster gap.
Feb 10, 2026
Projected Increase in New Drug Revenue by 1.5 Times... 'Competition for Clinical Superiority' Transforming...
The biopharmaceutical market is shifting towards "clinical superiority," with new drugs aiming to replace existing therapies by offering better efficacy or convenience. Notable contenders include Novonordisk's Cagrisema and Eli Lilly's Orforglipron in the GLP-1 class, projected to generate significant sales by 2032. Other candidates like Johnson & Johnson's Icotrokinra and AstraZeneca's Camizestrant also focus on improved efficacy.
Feb 10, 2026
AstraZeneca experiences continued expansion, driven by its oncology medications - The Edge Malaysia
AstraZeneca plc anticipates profit growth this year, driven by cancer drug sales, despite the patent expiry of its diabetes medication, Farxiga. CEO Pascal Soriot aims for $80 billion in revenue by 2030, with new medicines targeting obesity and lung cancer. Astra's recent $18.5 billion deal with CSPC Pharmaceutical Group enhances its obesity drug pipeline, including the oral GLP-1 drug, elecoglipron.
Feb 10, 2026
Kanpur SIT Steps Up Efforts Against Codeine Syrup Operation: Property Information Requested for 15 Individuals...
The Kanpur SIT has intensified its crackdown on an interstate racket involving the illegal trade of codeine-based cough syrup. Authorities are seeking property details for 15 accused individuals as part of the investigation, which focuses on the smuggling and sale of this controlled substance.
Feb 10, 2026
Hims faces challenges to its GLP-1 expansion due to a lawsuit from Novo and increased regulatory oversight - eMarketer
Novo Nordisk has filed a patent infringement lawsuit against Hims & Hers, alleging unlawful marketing of semaglutide, the active ingredient in Wegovy and Ozempic. Novo seeks a permanent ban on Hims' compounded drugs and financial damages. The FDA is also scrutinizing Hims for potential violations, raising concerns for the compounded weight loss drug market.
Feb 10, 2026
Novo Nordisk Initiates Patent Litigation Against Hims & Hers Regarding Compounded Semaglutide Items
Novo Nordisk has filed a lawsuit against Hims & Hers Health for allegedly infringing its semaglutide patent by marketing compounded weight loss drugs. The case, filed in Delaware, claims Hims unlawfully offers semaglutide products without FDA approval, violating Novo Nordisk's exclusive rights related to its drugs Ozempic, Wegovy, and Rybelsus. The court has yet to rule on the claims.
Feb 10, 2026
Lupin Reaches $90 Million Settlement with Astellas Over Drug Patent Conflict - Bloomberg Law News
Lupin Ltd. has settled its patent dispute with Astellas Pharma Inc. by agreeing to pay $90 million. The settlement, reached during trial, involves Lupin's admission of infringing several US patents related to a generic medication for overactive bladder. Lupin will refrain from producing or selling infringing products in the US until the patents expire.
Feb 10, 2026
Novo Nordisk files lawsuit against Hims & Hers for imitating Wegovy medications; Hims shares drop by 18%.
Novo Nordisk is suing Hims & Hers for marketing unapproved copies of its Wegovy obesity treatment in the U.S. The company seeks a permanent ban on Hims' sales of these compounded drugs and is pursuing damages. Novo's legal counsel criticized the situation as a "complete sham" following the end of a drug shortage.
Feb 10, 2026
Novo Nordisk files lawsuit against Hims for alleged patent violation regarding Wegovy | Virginia Lawyers Weekly
Novo Nordisk has filed a patent infringement lawsuit against Hims and Hers Health after the telehealth firm briefly launched a $49 version of Novo's weight-loss drug, Wegovy. The lawsuit highlights tensions between original drug manufacturers and compounding pharmacies. Novo seeks to ban Hims from selling unapproved drugs containing semaglutide, the active ingredient in Wegovy and Ozempic.
Feb 10, 2026
Uttarakhand FDA Suspends Production of Codeine-Infused Cough Syrup at Windlas Biotech Plant
The Uttarakhand FDA has halted the production of codeine-based cough syrup at Windlas Biotech's facility in Dehradun due to concerns over quality and potential misuse. This regulatory action underscores the increasing scrutiny on pharmaceutical manufacturing practices.
Feb 10, 2026
Delhi government conducts inspections at 25 companies and gathers 55 samples in a campaign against counterfeit anticancer medications.
The Delhi government conducted a special enforcement drive, inspecting 25 firms and collecting 55 samples in a crackdown on spurious and substandard anticancer drugs. This initiative aims to ensure the safety and efficacy of cancer treatments available in the city.
Feb 10, 2026
Wegovy manufacturer files lawsuit against competitor for producing 'imitation' weight-loss medications - BBC
The FDA announced plans to restrict the compounding of weight-loss drugs to protect consumers from products lacking verified quality, safety, or efficacy.
Feb 9, 2026
Pharmaceutical companies seek AI partnerships to offset revenue declines from expiring patents.
Pharmaceutical companies are increasingly turning to artificial intelligence (AI) to mitigate revenue losses from upcoming patent expirations, projected to cost $236 billion in US revenues by 2030. Notable collaborations include Eli Lilly's AI supercomputer project with NVIDIA and AstraZeneca's acquisition of Modella AI. Experts suggest AI could transform R&D, helping firms like In Silico and Valo Health enhance drug development efficiency.
Feb 9, 2026
Novo announces legal action against Hims to prevent imitation of its obesity medication - The Detroit News
Novo Nordisk A/S is suing Hims & Hers Health Inc. for patent infringement over semaglutide, the active ingredient in its obesity drugs Ozempic and Wegovy. Despite Hims' recent decision to halt plans for a copycat Wegovy pill, Novo claims Hims' products pose health risks and seeks damages. The lawsuit follows a turbulent week for Novo amid declining market capitalization.
Feb 9, 2026
Novo Nordisk files lawsuit against Hims following controversy over $49 weight-loss medication - RTE
Novo Nordisk has filed a lawsuit against Hims and Hers Health for patent infringement after Hims launched and then canceled a $49 version of Novo's weight-loss drug Wegovy, following FDA backlash. Novo's shares rose nearly 7%, while Hims' fell 20%. The FDA's crackdown on compounded GLP-1 drugs could impact competition in the obesity treatment market.
Feb 9, 2026
J&J Reports Growth in Innovative Medicines for 2025 Despite Stelara Patent Expiration - Yahoo Finance
Johnson & Johnson's Innovative Medicine segment achieved over $60 billion in sales for 2025, despite the loss of exclusivity for Stelara, which saw a 41.3% decline. Key products like Darzalex, Tremfya, and Erleada drove growth, with new drugs contributing significantly. J&J anticipates continued growth in 2026, targeting a 5% to 7% increase through 2030.
Feb 9, 2026
Hims & Hers Shares Drop as Novo Nordisk Sees Increase Amid New Developments in Weight-Loss Medication Competition
Hims & Hers Health (HIMS) shares plummeted 25% after announcing it would cease sales of its compounded semaglutide weight-loss pill, which mimicked Novo Nordisk's (NVO) Wegovy. Novo Nordisk has filed a lawsuit against Hims, seeking to ban the sale of unapproved drugs infringing its patents. The FDA plans to restrict compounded GLP-1 medications, impacting Hims' market position.
Feb 9, 2026
Wegovy's manufacturer files lawsuit against Hims & Hers for imitating weight loss medication | The Independent
Novo Nordisk has filed a lawsuit against Hims and Hers Health for patent infringement after the telehealth firm attempted to launch a $49 version of Novo's weight-loss drug, Wegovy. The lawsuit highlights tensions between obesity drug manufacturers and compounding pharmacies. Novo's shares rose nearly 6%, while Hims' stock fell 25%. The FDA is also restricting GLP-1 ingredients in compounded drugs.
Feb 9, 2026
J&J Reports Growth in Innovative Medicines for 2025 Despite Stelara Patent Expiration - Nasdaq
Johnson & Johnson's Innovative Medicine segment achieved $60.4 billion in sales for 2025, despite the loss of exclusivity for Stelara, which saw a 41.3% decline. Key products like Darzalex and Tremfya drove growth, with expectations for continued expansion in 2026. J&J's stock has risen 55.6% over the past year, outperforming the industry.
Feb 9, 2026
Novo Nordisk Files Lawsuit Against Hims & Hers for Imitating GLP-1 Product - Law360 Healthcare Authority
Novo Nordisk AS has filed a lawsuit against Hims & Hers Health Inc. in Delaware federal court, alleging that the telehealth company is marketing a knockoff of its GLP-1 drug. This legal action follows a plan announced by Novo Nordisk last week.
Feb 9, 2026
Could GLP-1 Compounding Indicate Patent Enforcement Beyond the Hatch-Waxman Act?
Recent developments regarding compounded GLP-1 products, particularly Hims & Hers Health Inc.'s plans to offer a compounded semaglutide pill, have raised concerns about patent enforcement outside the Hatch-Waxman framework. The article discusses the regulatory limits on compounding and highlights significant differences in patent litigation against compounders compared to traditional brand-generic disputes, emphasizing the need for branded companies to protect their intellectual property proactively.
Feb 9, 2026
Novo Nordisk stock rises following Hims' decision to discontinue weight-loss medication | News.az
Novo Nordisk shares rose 4.5% after Hims & Hers abandoned plans for a low-cost weight-loss pill based on semaglutide, following legal and regulatory pressure. The FDA's signals for tighter oversight of unauthorized compounded GLP-1 drugs contributed to the decision. Despite this rebound, Novo Nordisk faces ongoing competition and pricing pressures in the weight-loss and diabetes markets.
Feb 9, 2026
Wegovy manufacturer files lawsuit against Hims & Hers following the introduction of a $49 weight-loss medication - USA Today
Novo Nordisk has filed a federal lawsuit against telehealth provider Hims & Hers for allegedly infringing on its patent by selling compounded versions of its weight-loss drug Wegovy, which contains semaglutide. The lawsuit claims Hims & Hers is marketing unapproved versions that threaten patient safety. Hims & Hers argues the lawsuit limits consumer choice and undermines pharmacy practices.
Feb 9, 2026
Novo Nordisk experiences a significant rise as Hims withdraws its $49 weight loss medication due to FDA scrutiny.
Novo Nordisk has filed a patent infringement lawsuit against Hims and Hers Health after the telehealth company briefly launched a $49 version of Novo's weight-loss drug, Wegovy, which is based on the active ingredient semaglutide. The lawsuit highlights tensions between original drug manufacturers and compounding pharmacies, as Novo seeks to ban Hims from selling unapproved drugs and recover damages.
Feb 9, 2026
Analysts' Perspectives on Novo and Him & Hers Following Obesity Medication Recall - TradingView
Novo Nordisk's shares surged over 7% following Hims & Hers' decision to withdraw its oral obesity pill, a copycat of Novo's Wegovy, amid regulatory scrutiny. Novo has filed a lawsuit against Hims, claiming it is marketing unapproved versions of its drugs, jeopardizing patient safety. Hims' stock plummeted nearly 20% in premarket trading as a result.
Feb 9, 2026
Novo Nordisk Files Lawsuit Against Hims & Hers for Producing Lower-Cost Alternatives to Ozempic and Wegovy Weight Loss Medications
Novo Nordisk Pvt. Ltd. has filed a lawsuit against Hims & Hers Inc. for marketing unapproved, compounded versions of its weight loss drugs, Ozempic and Wegovy. The lawsuit seeks to prohibit Hims from selling these drugs and recover damages. Novo claims Hims' products contain dangerous impurities and infringe on its patents, escalating tensions in the competitive obesity drug market.
Feb 9, 2026
Novo Announces Legal Action Against Hims to Prevent Imitation of Obesity Medication - Claims Journal
Novo Nordisk A/S is suing Hims & Hers Health Inc. for patent infringement over semaglutide, the active ingredient in its obesity drugs Wegovy and Ozempic. Despite Hims abandoning plans for a copycat Wegovy pill, Novo's lawsuit targets all compounded forms of semaglutide. Hims claims the lawsuit limits consumer choice, while Novo argues it protects patient health.
Feb 9, 2026
BMY Rises 7.6% After Q4 Earnings Report: Is It Time to Buy, Sell, or Hold?
Bristol Myers Squibb (BMY) reported strong fourth-quarter 2025 results, boosting its stock by 7.6% to $61.99. Key growth drivers include Opdivo, Opdualag, Reblozyl, and Breyanzi, which collectively generated significant revenue. Despite facing generic competition impacting its legacy portfolio, BMY's pipeline and strategic collaborations, including with BioNTech, position it for future growth. The company targets $2 billion in cost savings by 2027.
Feb 9, 2026
The Initiative That Is Effectively Reducing Medication Costs - Families USA
In 2022, Congress passed the Inflation Reduction Act, empowering Medicare to negotiate drug prices, benefiting over 100 million Americans facing medical debt. The Centers for Medicare and Medicaid Services announced negotiations for 15 drugs, with prices set to drop significantly by January 2028. This program has already saved Medicare beneficiaries over $2 billion, contrasting with previous administration efforts that lacked transparency.
Feb 9, 2026
Novo Nordisk is taking legal action against Hims to stop the production of imitation obesity medications - Ad Age
Novo Nordisk has filed a lawsuit against Hims & Hers Health, alleging the company has produced knock-offs of its obesity medications, including the popular Wegovy pill, which was prominently featured in a Super Bowl advertisement.
Feb 9, 2026
The patent for Semaglutide is nearing its end, and India is prepared - Gulf News
The STEP-1 trial published in The New England Journal of Medicine revealed that adults with obesity or overweight lost an average of 15% of their body weight over 68 weeks with weekly semaglutide injections, compared to 2.4% in the placebo group. Participants also experienced improvements in blood pressure, cholesterol, and inflammation markers.
Feb 8, 2026
Successful Clinical Trial Enhances Potential for Roivant's Rare Disease Medication to Become a Blockbuster
Priovant Therapeutics, a subsidiary of Roivant Sciences, reported promising Phase 2 trial results for brepocitinib, a treatment for cutaneous sarcoidosis, showing significant skin improvement in patients. With no FDA-approved treatments available, brepocitinib's success could lead to a Phase 3 study and potential blockbuster sales. The drug is also being evaluated for dermatomyositis and non-infectious uveitis.
Feb 8, 2026
India's Semaglutide Patent Expiration Triggers Worldwide Surge in Generic Medications | Ukraine News - Межа
India is poised for a significant shift in the weight-loss drug market as the patent on semaglutide, the active ingredient in Novo Nordisk's Ozempic, expires in March 2025. Indian firms, including Dr. Reddy’s Laboratories and Cipla, are preparing to launch generics, potentially reducing prices by up to 90%. Eli Lilly's Mounjaro, a tirzepatide injection, is also gaining popularity in India.
